Health Care Stalls as Merck Slump Offsets Broader Pipeline Wins

On Monday, October 26, the exchange-traded fund Health Care Select Sector SPDR Fund (XLV) closed at 0.0%. Inside the fund, 53.0% of the graded weight sits in companies with an A or B quality grade, and market breadth was evenly split, with 49.2% of sector members advancing. Performance divided sharply among key holdings: a decline in Merck & Company Inc, which posted -3.2%, counterbalanced gains in life-sciences research suppliers where Charles River Laboratories posted +3.4%. Outside reporting points to a specific catalyst behind that drag: Merck retreated after investors mounted a sell-the-news reaction following clinical updates on its investigational melanoma vaccine. The stock also faced pressure as market participants weighed potential federal limits on Chinese biotechnology research partnerships.

While Merck weighed on the group, other large pharmaceutical names saw positive clinical momentum that kept the sector from slipping into negative territory. Pfizer secured expanded regulatory clearance from the Food and Drug Administration for its prostate cancer combination therapy Talzenna with Xtandi in an earlier disease setting. Oncology conference presentations added further support. Johnson & Johnson revealed encouraging early clinical findings for its experimental targeted prostate cancer candidate. Meanwhile, Bristol Myers Squibb highlighted positive late-stage trial outcomes across five Phase 3 studies evaluating its bispecific antibody-drug conjugate. In obesity therapeutics, Amgen outlined the clinical progress of its monthly injectable candidate across multiple ongoing late-stage trials.

The quiet session for the sector stood apart from the rest of the equity market, where 9 of the 11 sectors rose. While capitalization weighting kept the group at 0.0%, an equal-weighted slice stood at -0.1%. That slight divergence shows that the sector's largest companies held up better than the broader equal-weighted basket, preventing the fund from slipping into negative territory. Charles River Laboratories supported the sector's top tier, bolstered by expectations for solid quarterly bookings and operational execution ahead of upcoming financial results.

Over longer horizons, the fund has established substantial gains, showing +5.0% over the past month and +17.9% over the past 100 sessions. EasyAlpha grades each company against its industry peers. Companies graded A or B have stronger fundamentals, and historically they have carried a lower risk of large drawdowns than companies graded D or E. Across the fund, 53.0% of the graded weight sits in those top two tiers, though that historical distinction does not prevent individual company headlines from dictating short-term swings.